The market equates the GLP-1 revolution with two names: Eli Lilly and Novo Nordisk. Yet every dose of an injectable obesity or diabetes drug (Wegovy, Zepbound, Mounjaro, Ozempic) needs more than the molecule itself: pharmaceutical glass, elastomer stoppers and plungers, and a precision injector pen. As volumes scale, the real bottleneck moves away from chemistry and toward primary packaging and the delivery device.
The reason is structural. Injectable biologics require borosilicate glass held to tight specifications (vials, cartridges, syringes), elastomer closures with extremely low particulate and leachable levels, and validated pen and autoinjector platforms. Qualifying a new supplier takes years, ties up capital and runs straight into regulatory requirements. That is why the market is a narrow oligopoly in which capacity cannot be added overnight. With GLP-1 volumes running into hundreds of millions of doses a year, demand for these components structurally outruns constrained supply.